ClinicalTrials.gg
RecruitingNCT03947697Updated Oct 22, 2026

Improving Glycemic Control With Electrical Stimulation

An interventional study of Neuromuscular Electrical Stimulation (Sensory) and Neuromuscular Electrical Stimulation in Obesity, Overweight and Insulin Resistance, sponsored by University of Texas, El Paso. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by University of Texas, El Paso · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Once written consent is obtained, the participant will be provided with an accelerometer to be worn for 7 days to assess current physical activity levels. Subjects will be provided with a standardized diet (55/15/30% CHO/PRO/FAT) prior to collection of pre-intervention data of insulin sensitivity. Individuals will then participate in an 8-week electrical stimulation intervention (30min/day, 3x/week) and randomized into placebo/control, NMES, resistance training combined with NMES (RT +NMES), or resistance training (RT) group (n=15 per group), followed by collection of post-intervention data. The control group will receive electrical stimulation up to sensory level, the NMES group will receive stimulation up to tolerable intensity to induce visible muscle contraction, the RT+ NMES will receive stimulation up to tolerable intensity during resistance training, and the RT group will only receive exercise training. Pre-and post-intervention data includes measurements for body composition, resting metabolic rate, VO2max, insulin sensitivity, and comprehensive blood work.

02

Conditions studied

  • Obesity
  • Overweight
  • Insulin Resistance

Keywords

  • Obesity
03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's planned enrollment of 60 is below the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

University of Texas, El Paso is the lead sponsor of 21 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overweight/Obese ( ≥25)
  • Sedentary Lifestyle: Physical Activity Level\<1.4
  • Less than 150min/week of structured Exercise

Exclusion criteria

Exclusion Criteria:

  • Use of anti-hypertensive, lipid-lowering or insulin sensitizing medications
  • Excessive alcohol, drug abuse, smoking
  • Pregnant Women
  • Unwilling to adhere to the study Intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Placebo comparator
    Control

    Participants will receive stimulation only up to sensory level.

    Device: Neuromuscular Electrical Stimulation (Sensory)

  • Experimental
    NMES

    Participants will receive stimulation up to maximum tolerable level.

    Device: Neuromuscular Electrical Stimulation

  • Placebo comparator
    Resistance Training

    Participants will receive exercise training with stimulation up to sensory level.

    Device: Neuromuscular Electrical Stimulation (Sensory) · Other: Resistance Training

  • Experimental
    Resistance Training + NMES

    Participants will receive exercise training with stimulation up to maximum tolerable intensity.

    Device: Neuromuscular Electrical Stimulation · Other: Resistance Training

Interventions

  • DeviceNeuromuscular Electrical Stimulation (Sensory)

    Group will receive Electrical Stimulation up to sensory level

    Also known as: Control

  • DeviceNeuromuscular Electrical Stimulation

    Group will receive Electrical Stimulation up to maximum tolerable level

    Also known as: NMES Group

  • OtherResistance Training

    Group will receive exercise training.

06

What researchers measure

Primary outcomes

  1. Glycemic Control

    Insulin Sensitivity will be measured through repeated blood sampling during an Oral Glucose Tolerance Test and Continuous Glucose Monitoring

    Time frame: 8 weeks

Secondary outcomes

  1. Respiratory Exchange Ratio

    Respiratory Exchange Ratio will be used to quantify substrate utilization (fats vs carbohydrates) through the use of indirect calorimetry of in vivo gas exchange

    Time frame: 8 Weeks

  2. Amount of lean mass

    Amount of lean mass will be measured by dual energy x-ray absortiometry

    Time frame: 8 Weeks

07

Study locations

1 of 1 sites recruiting
  • University of Texas at El Paso
    El Paso, Texas 79968, United States
    Recruiting
    • Sudip R Bajpeyi, PhD · Contactsbajpeyi@utep.edu · 9157475461
    • Michelle Galvan, B.S. · Sub investigator
    • Jehu N Apaflo, M.S. · Sub investigator
    • Gabriel Narvaez, B.S. · Sub investigator
08

References and documents

Publications

  • Apaflo JN, Narvaez G, Tomy IJ, Mossayebi A, Fatahimeiabadi Z, McAinch AJ, Thyfault JP, Min K, Jung H, Wagler AE, Bajpeyi S. Neuromuscular electrical stimulation enhances glycemic control and carbohydrate utilization in sedentary, predominantly Hispanic overweight or obese individuals with hyperglycemia. Eur J Appl Physiol. 2026 Jan;126(1):469-477. doi: 10.1007/s00421-025-05907-x. Epub 2025 Jul 28. PubMed 40721518 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Nov 2026, 51 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 51 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2018
First posted
May 13, 2019
StartActual
Aug 9, 2022
Primary completionEst.
Nov 25, 2026
CompletionEst.
Apr 30, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40721518 ↗
Oct 22, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Texas at El Paso · El Paso, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40721518 ↗
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Texas at El Paso · El Paso, United StatesContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact person changed (no phone or email listed)
    + 4 other changes: index terms, identifiers, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03947697
Lead sponsor
University of Texas, El Paso
Responsible party
Sudip Bajpeyi (Associate Professor, University of Texas, El Paso) — Principal investigator
First posted
May 13, 2019
Start date
Aug 9, 2022
Primary completion
Nov 25, 2026 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Sudip Bajpeyi, PhD
Contact
sbajpeyi@utep.edu
9157475461

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion